Nymox Pharma (NYMX) PR is a Repeat of Same Talking Points - Feuerstein
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Nymox's New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show
August 29, 2016 10:30 AM EDT1. Dramatic Decrease in Prostate Cancer and
2. Major Reduction in Need For BPH Prostate Surgery
HASBROUCK HEIGHTS, N.J., Aug. 29, 2016 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq: NYMX) lead drug fexapotide which has been in development for over a decade and which has been... More
